JP2022533438A5 - - Google Patents

Info

Publication number
JP2022533438A5
JP2022533438A5 JP2021569402A JP2021569402A JP2022533438A5 JP 2022533438 A5 JP2022533438 A5 JP 2022533438A5 JP 2021569402 A JP2021569402 A JP 2021569402A JP 2021569402 A JP2021569402 A JP 2021569402A JP 2022533438 A5 JP2022533438 A5 JP 2022533438A5
Authority
JP
Japan
Prior art keywords
aav
acid sequence
amino acid
protein
capsid protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021569402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533438A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/034328 external-priority patent/WO2020242984A1/en
Publication of JP2022533438A publication Critical patent/JP2022533438A/ja
Publication of JP2022533438A5 publication Critical patent/JP2022533438A5/ja
Priority to JP2024196799A priority Critical patent/JP2025032110A/ja
Priority to JP2025085876A priority patent/JP2025119015A/ja
Pending legal-status Critical Current

Links

JP2021569402A 2019-05-24 2020-05-22 改変ウイルス粒子およびその使用 Pending JP2022533438A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024196799A JP2025032110A (ja) 2019-05-24 2024-11-11 改変ウイルス粒子およびその使用
JP2025085876A JP2025119015A (ja) 2019-05-24 2025-05-22 改変ウイルス粒子およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852791P 2019-05-24 2019-05-24
US62/852,791 2019-05-24
PCT/US2020/034328 WO2020242984A1 (en) 2019-05-24 2020-05-22 Modified viral particles and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024196799A Division JP2025032110A (ja) 2019-05-24 2024-11-11 改変ウイルス粒子およびその使用

Publications (2)

Publication Number Publication Date
JP2022533438A JP2022533438A (ja) 2022-07-22
JP2022533438A5 true JP2022533438A5 (enExample) 2023-05-30

Family

ID=71094822

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021569402A Pending JP2022533438A (ja) 2019-05-24 2020-05-22 改変ウイルス粒子およびその使用
JP2024196799A Pending JP2025032110A (ja) 2019-05-24 2024-11-11 改変ウイルス粒子およびその使用
JP2025085876A Pending JP2025119015A (ja) 2019-05-24 2025-05-22 改変ウイルス粒子およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024196799A Pending JP2025032110A (ja) 2019-05-24 2024-11-11 改変ウイルス粒子およびその使用
JP2025085876A Pending JP2025119015A (ja) 2019-05-24 2025-05-22 改変ウイルス粒子およびその使用

Country Status (19)

Country Link
US (1) US20220241430A1 (enExample)
EP (1) EP3976631A1 (enExample)
JP (3) JP2022533438A (enExample)
KR (1) KR20220011664A (enExample)
CN (2) CN113874386A (enExample)
AR (2) AR118997A1 (enExample)
AU (1) AU2020283537A1 (enExample)
BR (1) BR112021023692A2 (enExample)
CA (1) CA3140386A1 (enExample)
CL (2) CL2021003096A1 (enExample)
CO (1) CO2021017692A2 (enExample)
IL (1) IL288233A (enExample)
MA (1) MA56035A (enExample)
MX (1) MX2021014338A (enExample)
PE (1) PE20212357A1 (enExample)
PH (1) PH12021552887A1 (enExample)
SG (1) SG11202112917PA (enExample)
TW (1) TW202110869A (enExample)
WO (1) WO2020242984A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019227910B2 (en) 2018-02-28 2025-07-17 The Regents Of The University Of California A modular system for gene and protein delivery based on AAV
JP2022533438A (ja) * 2019-05-24 2022-07-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改変ウイルス粒子およびその使用
US20240124892A1 (en) * 2021-03-02 2024-04-18 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Adeno-associated viruses and methods and materials for making and using adeno-associated viruses
WO2022232575A1 (en) * 2021-04-30 2022-11-03 Duke University Compositions comprising adeno-associated virus chimera capsid proteins and methods of using the same
CA3222914A1 (en) * 2021-06-23 2022-12-29 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
US20250302998A1 (en) 2022-05-09 2025-10-02 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2025042462A2 (en) * 2023-08-24 2025-02-27 Ohio State Innovation Foundation Assays and methods for quality control of genome packaging for gene therapy
TW202528546A (zh) * 2023-09-07 2025-07-16 美商再生元醫藥公司 經共價表面修飾之腺相關病毒的生產及純化
TW202540433A (zh) * 2023-11-21 2025-10-16 美商再生元醫藥公司 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化
WO2026037757A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag Modified aav particles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2224907A1 (en) * 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
WO1998011244A2 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
WO1999061601A2 (en) 1998-05-28 1999-12-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav5 vector and uses thereof
ATE362542T1 (de) 1998-11-05 2007-06-15 Univ Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
MX359371B (es) * 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
ES2602610T3 (es) 2007-05-31 2017-02-21 Medigene Ag Proteína estructural mutada de un parvovirus
ES2724975T3 (es) 2009-12-10 2019-09-18 Regeneron Pharma Ratones que producen anticuerpos de cadena pesada
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
ES2926774T3 (es) * 2013-03-15 2022-10-28 Univ North Carolina Chapel Hill Métodos y composiciones para vectores AAV de doble unión de glicano
CA2942289C (en) * 2014-03-10 2024-05-21 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
EP3151866B1 (en) * 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
US10550405B2 (en) * 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
PE20200488A1 (es) 2017-06-27 2020-03-03 Regeneron Pharma Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas
LT3645553T (lt) * 2017-06-27 2023-04-25 Regeneron Pharmaceuticals, Inc. Modifikuoto tropizmo rekombinantinės viruso dalelės ir jų panaudojimas genetinės medžiagos tiksliniam įvedimui į žmogaus ląsteles
AU2019227910B2 (en) * 2018-02-28 2025-07-17 The Regents Of The University Of California A modular system for gene and protein delivery based on AAV
JP2022533438A (ja) * 2019-05-24 2022-07-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改変ウイルス粒子およびその使用

Similar Documents

Publication Publication Date Title
JP2022533438A5 (enExample)
Wagner et al. Synthetic biology: emerging concepts to design and advance adeno‐associated viral vectors for gene therapy
US20240197918A1 (en) Tissue-targeted modified aav capsids and methods of use thereof
WO2020160337A1 (en) Systems for evolved adeno-associated viruses (aavs) for targeted delivery
JP2023171525A (ja) Aavキメラ
KR20190032375A (ko) 신규 아데노-관련 바이러스 캡시드 단백질
CN112041442A (zh) 用于逃避抗体的病毒载体的方法和组合物
IL317938A (en) Recombinant viral vectors with altered tropism and their uses for the targeted introduction of genetic material into human cells
US12398403B2 (en) Methods for the manufacture of recombinant viral vectors
JP2025119015A (ja) 改変ウイルス粒子およびその使用
JP2024050766A (ja) 改変ウイルスカプシド
JP2024540181A5 (enExample)
US20180016328A1 (en) Anti-tau constructs
JP2021520837A5 (enExample)
JP2025517628A (ja) 新規の組換えaav vp2融合ポリペプチド
TW201920676A (zh) 具有經修飾之磷脂酶區域的腺相關病毒(aav)
JP2025004107A (ja) ガラクトース血症の処置のための遺伝子治療
AR123948A1 (es) ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES
US20240050476A1 (en) Combination of deoxyribonuclease enzyme and cell therapies for treatment of cancer
RU2021133286A (ru) Модифицированные вирусные частицы и пути их применения
Mann et al. Enhanced transduction of P2X7-expressing cells with recombinant rAAV vectors
Weinmann Massively parallel in vivo characterization of novel adeno-associated viral (AAV) capsids using DNA/RNA barcoding and next generation sequencing
RU2020101596A (ru) Рекомбинантные вирусные частицы с модифицированным тропизмом и пути их применения для нацеленного введения генетического материала в клетки человека
RU2024111148A (ru) Вирусные частицы, перенацеленные на скелетные мышцы
Xu et al. Capsid modification of adeno-associated virus and tumor targeting gene therapy